Is Global Health the Best Stock in Its Sector? A Look at the Numbers
- September 15, 2026
- Posted by: Harsh Piplani
- Category: Market
Global Health CMP Rs 1,427 (15 Sep 2026). Market cap Rs 38,921 Cr. ROE 14.05%. P/E 70.47x versus Industry P/E 67.99x.
Quick Answer
Global Health is one of the names investors compare when screening the Healthcare sector, built on a 14.05% return on equity and a P/E of 70.47x against an Industry P/E of 67.99x. Global Health Ltd operates the Medanta chain of multi-specialty hospitals across North India, offering tertiary and quaternary care across cardiology, oncology, neurosciences and other specialties. Whether Global Health is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.
Is Global Health the best stock in its sector? The stock trades on the NSE at Rs 1,427 as of 15 September 2026, within its 52-week range of Rs 956.00 to Rs 1,544.00. Global Health Ltd operates the Medanta chain of multi-specialty hospitals across North India, offering tertiary and quaternary care across cardiology, oncology, neurosciences and other specialties.
Global Health sits in the Healthcare sector, and its 14.05% ROE and 70.47x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Global Health
Global Health Ltd operates the Medanta chain of multi-specialty hospitals across North India, offering tertiary and quaternary care across cardiology, oncology, neurosciences and other specialties. At a market capitalisation of Rs 38,921 Cr, it is tracked as part of the Healthcare sector on Univest.
Is Global Health the Best Stock in Its Sector?
Global Health makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 14.05% ROE with a 70.47x P/E against the sector’s 67.99x Industry P/E. Global Health trades close to its 67.99x Industry P/E, with a 14.05% ROE ahead of Gland Pharma’s in this comparison but behind the more asset-light MNC pharma names.
| Metric | Global Health |
|---|---|
| CMP (NSE) | Rs 1,426.80 |
| 52-Week High / Low | Rs 1,544.00 / Rs 956.00 |
| Market Cap | Rs 38,921 Cr |
| P/E (TTM) vs Industry P/E | 70.47x vs 67.99x |
| P/B | 9.82 |
| ROE | 14.05% |
| EPS (TTM) | Rs 20.54 |
| Dividend Yield | 0.03% |
| Debt to Equity | 0.30 |
Compare Global Health Against Other Healthcare Sector Stocks
How Global Health Compares Against Its Healthcare Sector Peers
The table below sets Global Health against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Global Health | 38,921 | 70.47 | 14.05% | 0.30 |
| Gland Pharma | 48,215 | 42.71 | 9.92% | 0.03 |
| Emcure Pharmaceuticals | 37,499 | 36.80 | 18.67% | 0.31 |
| Peer average (2 companies) | – | 39.75 | 14.30% | 0.17 |
Against this peer set, Global Health’s 14.05% ROE is below the 14.30% peer average, and its P/E of 70.47x runs above the peer average of 39.75x. Global Health trades close to its 67.99x Industry P/E, with a 14.05% ROE ahead of Gland Pharma’s in this comparison but behind the more asset-light MNC pharma names.
What Makes Global Health Worth Watching in Healthcare
- Solid ROE for hospitals: A 14.05% ROE is a healthy figure for a hospital operator carrying significant fixed medical infrastructure.
- Close to Industry P/E: A 70.47x P/E versus a 67.99x Industry P/E shows Global Health trading close to Healthcare sector norms.
- Established multi-specialty brand: The Medanta brand’s reputation in tertiary and quaternary care supports patient volumes and pricing across its hospital network.
Global Health Valuation: Is It Justified?
Global Health trades close to its 67.99x Industry P/E, with a 14.05% ROE ahead of Gland Pharma’s in this comparison but behind the more asset-light MNC pharma names. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Bata India the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Global Health and other Healthcare sector stocks.
How to Track Global Health Before You Invest
Before deciding whether Global Health deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.
- Open the Univest Screener and search for Global Health to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
- Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Global Health earns a place in the best stock in its sector conversation on the strength of a 14.05% ROE and a P/E of 70.47x against a 67.99x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Global Health the best stock in its sector?
Ans. Global Health has a 14.05% ROE and trades at 70.47x P/E against a 67.99x Industry P/E, and compares below the peer average ROE of 14.30% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Global Health?
Ans. Global Health was trading at Rs 1,426.80 on the NSE as of 15 September 2026, within its 52-week range of Rs 956.00 to Rs 1,544.00.
What sector does Global Health belong to?
Ans. Global Health is classified under the Healthcare sector on Univest.
How does Global Health compare to its sector peers on P/E?
Ans. Global Health’s P/E of 70.47x is above the 39.75x average of the 2 named peers compared in this article.
What is Global Health’s return on equity?
Ans. Global Health reported a return on equity of 14.05%, which is below the 14.30% average of its named peers in this comparison.
Should I invest in Global Health based on its sector position?
Ans. Global Health’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.
